Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD8586 vs Investigator's Choice in Relapsed/Refractory CLL/SLL
NCT07139873Phase 3Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of birelentinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Sep 2025; status: recruiting.
02
Drugs
birelentinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07139873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139873.